Buy Epithalon Peptide: The Red Cap Is on the Certificate

Buy Epithalon peptide from a research supplier and the thing that arrives is a sealed glass vial holding a few milligrams of white lyophilised powder under a red cap. It is small, it is unremarkable to look at, and almost everything worth knowing about it is printed on a separate document.

This page is about laying those two objects side by side. The batch report for the lot linked below does something most certificates in this market do not: it describes the physical container as well as its contents, down to the colour of the closure. That turns the arrival of a parcel into a check rather than an act of faith, and it is a more useful thing to write about than an unboxing.

The listing this page examines:

What you get when you buy Epithalon peptide in a 10 mg vial

Epithalon is a synthetic tetrapeptide: four residues, alanine, glutamic acid, aspartic acid and glycine, in that order. PubChem lists it under CID 219042 with the formula C14H22N4O9 and a molecular weight of 390.35, and files it as Epitalon, which is the spelling FDA also uses. The market writes Epithalon. Both names point at the same molecule, and the CAS number on the certificate, 307297-39-8, is the identifier that settles it without reference to either spelling.

At 390 daltons this is a very small peptide by the standards of the compounds this site usually covers, which is worth registering because it changes the analytical picture. Four residues means very little sequence for synthesis to get wrong, and correspondingly little scope for the truncated and deleted sequences that dominate the impurity profile of longer peptides. It also means the mass in the vial is a small absolute quantity of a light molecule, and small quantities are harder to fill accurately than large ones.

The physical form is lyophilised powder, which is freeze-dried solid. Peptides are supplied this way because water is what drives most of the chemistry that degrades them, and removing it turns a compound with a shelf life measured in days into one with a shelf life measured in months or years under cold storage. The trade is that the solid has to be dissolved again before it is any use, and the moment of dissolving is the moment the document stops applying.

The label says 10 mg and the certificate says 9.64 mg

A number on a label is a target. A number on a certificate is a measurement, and on the certificate for batch 15-05260628, certified 23 May 2026 by Kovera Labs under report KVR-2026-A36FF4, the net content line reads 9.64 mg against a specification of 10 mg plus or minus 10 percent.

It passes. The accepted band is 9.00 mg to 11.00 mg and 9.64 mg sits inside it, 3.6 percent below the printed figure. It also costs the seller money to publish, because it moves the honest per-milligram figure from $2.50 to $2.59 at the discounted price. A vendor printing a number that runs against its own listing is the most informative thing on the page, and it is worth more than the purity percentage that sits above it. We work the arithmetic through in full, including what happens if you try to fold the purity figure in as well, in our breakdown of what an Epithalon milligram costs.

The general lesson is that a label states an intention and a fill weight is an outcome. Filling small masses of low-density freeze-dried solid is a mechanical process with real variance, which is exactly why a tolerance exists. Ask for the certificate carrying the batch number printed on your vial and read that document rather than this one, because the 9.64 mg belongs to a lot filled in May 2026 and to nothing else. The same check on another compound at the same supplier turned up a lot that came in above its label rather than below, which is the same variance pointing the other way.

Matching the document to the object in your hand

Five fields on this certificate describe things you can see without any equipment. That is unusual, and it is the practical reason to download the PDF before the parcel arrives rather than after.

There is a sixth check that does not involve the vial at all. The certificate prints a report number and an access code beside the address of a verification page hosted by the issuing laboratory, which is a route to confirming the document with the party that produced it rather than the party that published it. We describe that mechanism rather than its output, because we have not run it.

Why the powder format decides which tests are possible

A certificate can only answer questions the format allows it to ask. A sealed vial of lyophilised solid supports a specific set: chromatographic purity, identity by mass spectrometry, a weight, a heavy metals screen, a bacterial endotoxin measurement and a sterility screen on the closed container. This batch carries all six, which is more than a research-supply certificate usually does.

Two of them are the ones that exist because of the format. Endotoxin is a heat-stable fragment of gram-negative bacterial cell wall that survives sterilisation and is invisible in a chromatogram, so it needs a dedicated assay, and this document records a pass against a limit of 0.5 EU/mL or below without naming the method or printing a value. The compendial reference procedure for that assay is USP Chapter 85, and a certificate that cites it tells you more than one that does not. The sterility result is likewise recorded as a screen returning no growth rather than as the full compendial test, and the difference between those two things is a matter of incubation time and method rather than wording.

How much the format constrains the paperwork is easiest to see by comparison. We set out what changes when the same compound class is sold as a solution in a metering bottle rather than a sealed vial in our comparison of a spray against a lyophilised vial, where a whole category of question opens up that no powder assay can answer. The equivalent question-set for a different compound sold in the same powder format is worked through in our look at what a BPC-157 vial physically contains.

Where the certificate stops covering the object

Lyophilised peptide is stable as a solid because the water that drives hydrolysis has been removed, and suppliers ship it cold and recommend cold storage on arrival for that reason. Two of the six results on the document describe that solid and will keep describing it: identity does not change on a shelf, and the metals present in the material are the metals that were present when it was analysed. Purity and net content describe the state of the material at the moment of analysis and can only degrade from there.

The other two are different in kind. Endotoxin and sterility are properties of a closed container. The moment the crimp is opened, a stopper is pierced and a liquid is introduced, the object stops being the object the laboratory tested, and its microbiological status becomes a function of the environment it was opened in rather than of the batch it came from. This page carries no preparation instructions, no solvents and no quantities, and that is not squeamishness. It is that the interesting analytical statement ends at the seal, and a document cannot be extended past it.

There is a related reason the format matters for this specific compound. FDA’s stated concern about epitalon is immunogenicity arising from aggregation and peptide-related impurities, and aggregation is a physical-state phenomenon rather than a chemical one: the same molecules, associated into particles. The peer-reviewed literature on therapeutic protein aggregates treats their immunogenic potential as a function of size, count and the conditions of handling, which are the variables that a freeze-dried solid keeps stable and a reconstituted solution does not. A purity figure of 99.312 percent says a great deal about impurity and nothing at all about aggregation state.

What the vial cannot tell you

Six results on one page put this document ahead of most of what circulates in this market. None of them touch the question people are actually buying against. Epithalon is sold on telomere and longevity claims that trace overwhelmingly to one research group in St Petersburg, whose 2004 report of human somatic cells continuing to divide past their usual limit in culture is the paper most often cited for them. That is cell culture, it is one group, and it is not a registered controlled human trial. This site reports the claims and who makes them; it does not adopt them, and nothing here should be read as saying that this compound extends human life.

The regulatory record is equally short. There is no FDA approval for any indication. The nomination that would have placed epitalon on the compounding bulks list was withdrawn, and the compound appears in none of the three categories of the 503A list updated on 14 May 2026. FDA states that compounded drugs containing epitalon may pose a risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities, and that it lacks sufficient information to know whether the drug would cause harm if administered to humans. For how this site grades material sold under research-use terms generally, see what research-use supply actually means.